SAN DIEGO--(BUSINESS WIRE)--Jun. 6, 2019--
DexCom, Inc. (NASDAQ:DXCM) and Companion Medical, Inc. today announced a
collaboration to enable a direct exchange of CGM data from Dexcom with
insulin data from InPen™ into both companies’ software applications.
This agreement is the first of its kind and paves the way for advanced
diabetes decision support, an important tool for insulin users.
Dexcom and Companion Medical are working together to develop a seamless
data transfer of both insulin and glucose information. This
collaboration enables both companies to offer advanced features and
algorithms to improve in-the-moment decisions for those managing their
diabetes with multiple daily injections. Advanced decision support
requires multiple inputs, including current glucose, glucose trend,
carbohydrate intake, accurate insulin dosing and insulin-on-board.
“Dexcom is committed to helping people make better therapy decisions
based on their glucose levels, and Companion is committed to helping
people make better insulin dosing decisions. These decisions are
synchronous to the person living with diabetes which provides a
compelling opportunity for our teams to work together,” said Steve
Pacelli, EVP of Strategy and Corporate Development at Dexcom.
“We are pleased to be partnering with Dexcom on this important mission.
Improving outcomes for people on multiple daily injections requires
bringing together the two critical factors of diabetes management --
glucose and insulin -- in real-time. We are the first two companies with
the technology capable of providing an integrated solution," said Sean
Saint, CEO of Companion Medical.
As a first step in this collaboration, Dexcom and Companion Medical will
enable InPen users to display long-acting and rapid-acting insulin data
in the Dexcom CLARITY Diabetes Management Software. Dexcom CGM data is
currently available in the Companion Medical Insights by InPen report.
This integration enables health care providers to access a combined,
comprehensive view of a patient’s therapy plan, increasing the
effectiveness of how and when patients should dose and paving the way
for improved and transparent treatment decisions.
The InPen/CLARITY report integration will be launched and available for
preview at the upcoming American Diabetes Association Conference in San
Francisco. Both companies are actively developing their real-time
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping
people better manage their diabetes by developing and marketing
continuous glucose monitoring (CGM) products and tools for adult and
pediatric people with diabetes. With exceptional performance, comfort
and lifestyle flexibility at the heart of its technology, users have
consistently ranked DexCom highest in customer satisfaction and loyalty.
For more information on the Dexcom CGM, visit www.dexcom.com.
About Companion Medical, Inc.
Companion Medical is a leader in the development of advanced technology
to improve diabetes care. InPen™, the first and only FDA-cleared smart
insulin pen, combines an innovative diabetes management app with a
Bluetooth® enabled pen injector to simplify the constant tracking,
monitoring and calculating required for insulin therapy. InPen addresses
many of the issues that people living with diabetes face on a daily
basis, including missed insulin doses, miscalculated insulin doses and
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005174/en/
Source: DexCom, Inc.
Dexcom Investor Contact:
Steve Pacelli, 858-200-0200
Dexcom Press Contact:
James McIntosh, 619-884-2118
Companion Medical Media Contact: